UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma

Blood cancer journal (New York), 2023-02, Vol.13 (1), p.25-25, Article 25

2023

Volltextzugriff (PDF)

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.10174-10176

2022

Volltextzugriff (PDF)

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.9933-9934

2022

Volltextzugriff (PDF)

A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial

British journal of haematology, 2021-08, Vol.194 (3), p.580-586

2021

Volltextzugriff (PDF)

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.1665-1665

2021

Volltextzugriff (PDF)

The Effect of Daratumumab, Lenalidomide, Dexamethasone (DRd) on Peripheral Blood Stem Cell Mobilisation (PBSC)

Blood, 2021-11, Vol.138 (Supplement 1), p.3884-3884

2021

Volltextzugriff (PDF)

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Blood, 2021-11, Vol.138 (Supplement 1), p.1671-1671

2021

Volltextzugriff (PDF)

Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis

Blood, 2018-11, Vol.132 (Supplement 1), p.3265-3265

2018

Volltextzugriff (PDF)

Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.1663-1663

2021

Volltextzugriff (PDF)

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Blood, 2019-11, Vol.134 (Supplement_1), p.3144-3144

2019

Volltextzugriff (PDF)

Abstract 782: Circulating tumour DNA-based molecular response predicts treatment outcome in multiple myeloma

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.782-782

2023

Volltextzugriff (PDF)

OAB-048: An interim analysis of a phase I/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: AMaRC 19-02 BelaCarD study

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S29-S30

2022

Volltextzugriff (PDF)

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.3090-3090

2019

Volltextzugriff (PDF)

P-055: Extracellular RNA: an emerging biomarker for therapeutic monitoring in multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S68-S69

2021

Volltextzugriff (PDF)

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Blood, 2018-11, Vol.132 (Supplement 1), p.333-333

2018

Volltextzugriff (PDF)

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Blood, 2018-11, Vol.132 (Supplement 1), p.3279-3279

2018

Volltextzugriff (PDF)

Abstract 3373: Circulating tumour DNA mutations correlate with relapse in a phase II trial of bortezomib-primary refractory multiple myeloma patients receiving salvage therapy

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3373-3373

2022

Volltextzugriff (PDF)

Attitudes toward neonatal intensive care treatment of preterm infants with a high risk of developing long-term disabilities

Pediatrics (Evanston), 2009-06, Vol.123 (6), p.1501-1508

2009

Volltextzugriff (PDF)

A Chopstick in the Nose

Journal of the Royal Society of Medicine, 2002-12, Vol.95 (12), p.614-615

2002

Volltextzugriff (PDF)

Early Diagnosis of Intra-Abdominal Inflammation and Sepsis by Neutrophil CD64 Expression in Newborns

Neonatology (Basel, Switzerland), 2011-02, Vol.99 (2), p.118-124

2011

Volltextzugriff (PDF)

A chopstick in the nose

Journal of the Royal Society of Medicine, 2002-12, Vol.95 (12), p.614-615

2002

Volltextzugriff (PDF)

26.1 Biological Action of Ketamine in Developing Neurons: Hope in Treating Maternal Depression to Reduce Children Mood Disorders

Journal of the American Academy of Child and Adolescent Psychiatry, 2021-10, Vol.60 (10), p.S201-S201

2021

Volltextzugriff (PDF)

S58. Functional Characterization of Brain Organoids Derived From Human Pluripotent Stem Cells

Biological psychiatry (1969), 2018-05, Vol.83 (9), p.S369-S369

2018

Volltextzugriff (PDF)

Abstract 10283: Socioeconomic Disparities in Overall and Morbidity Free Survival of Infants With Single Ventricle Heart Disease

Circulation (New York, N.Y.), 2022-11, Vol.146 (Suppl_1)

2022

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(59)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

The Effect of Daratumumab, Lenalidomide, Dexamethasone (DRd) on Peripheral Blood Stem Cell Mobilisation (PBSC)

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis

Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Abstract 782: Circulating tumour DNA-based molecular response predicts treatment outcome in multiple myeloma

OAB-048: An interim analysis of a phase I/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: AMaRC 19-02 BelaCarD study

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

P-055: Extracellular RNA: an emerging biomarker for therapeutic monitoring in multiple myeloma

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Abstract 3373: Circulating tumour DNA mutations correlate with relapse in a phase II trial of bortezomib-primary refractory multiple myeloma patients receiving salvage therapy

Attitudes toward neonatal intensive care treatment of preterm infants with a high risk of developing long-term disabilities

A Chopstick in the Nose

Early Diagnosis of Intra-Abdominal Inflammation and Sepsis by Neutrophil CD64 Expression in Newborns

A chopstick in the nose

26.1 Biological Action of Ketamine in Developing Neurons: Hope in Treating Maternal Depression to Reduce Children Mood Disorders

S58. Functional Characterization of Brain Organoids Derived From Human Pluripotent Stem Cells

Abstract 10283: Socioeconomic Disparities in Overall and Morbidity Free Survival of Infants With Single Ventricle Heart Disease

Suchergebnisse filtern